FOXO4-DRI is a senolytic D-retro-inverso peptide engineered from the FOXO4 sequence to disrupt the FOXO4-p53 protein interaction that keeps senescent cells alive, releasing p53 to drive nuclear exclusion and intrinsic mitochondrial apoptosis selectively in senescent cells. First reported by de Keizer and colleagues in 2017, every FOXO4-DRI finding derives from cell and mouse studies, and Apex Laboratory supplies it strictly as a research-use-only chemical reagent.
Cellular senescence — a state of stable, essentially irreversible cell-cycle arrest — is one of the defined hallmarks of aging, and senescent cells accumulate in tissues over a lifetime where they secrete a pro-inflammatory program and resist their own removal.[1] One of the molecular safeguards that keeps these cells alive is a protein-protein interaction between the transcription factor FOXO4 and the tumour suppressor p53. FOXO4-DRI is a designed peptide built specifically to break that interaction: a senolytic D-retro-inverso peptide that, in published preclinical work, competes with endogenous FOXO4 for p53 and thereby releases p53 to drive apoptosis selectively in senescent cells.[2]
This guide summarizes the FOXO4-DRI research literature for laboratory context — the FOXO4 and p53 biology behind the target, the D-retro-inverso engineering that gives the peptide its name, the p53-nuclear-exclusion apoptosis mechanism, and the cell and mouse models in which it has been studied. FOXO4-DRI sits within the Apex longevity and bioregulator research peptides cluster, and it is supplied strictly as a research-grade chemical reagent for in-vitro and preclinical investigation — not as a drug, dietary product, or therapy for human or veterinary use.
FOXO4-DRI at a Glance
- FOXO4-DRI is a senolytic D-retro-inverso peptide that targets the FOXO4–p53 interaction, first reported in Baar et al. 2017 (Cell) from Peter de Keizer’s group at Erasmus MC.
- In senescent cells, FOXO4 sequesters p53 in PML nuclear bodies to block apoptosis; FOXO4-DRI competes with endogenous FOXO4 and frees p53.
- The “DRI” design — all-D amino acids in reversed sequence — confers protease resistance while preserving side-chain topology and cell penetration.
- In studied models, p53 nuclear exclusion drives intrinsic / mitochondrial apoptosis (BAX, cleaved caspase-3) selectively in senescent over proliferating cells.
- Preclinical mouse work reported restored renal function, fitness, and fur density in aged and fast-aging mice, with additional models in Leydig cells, fibroblasts, and lung fibrosis.
- All FOXO4-DRI data are in-vitro and animal-model; Apex supplies it strictly as a research-grade reagent at ≥99% purity (HPLC + MS) — no approved formulation exists and there is no human dosing guidance.
FOXO4-DRI (FOXO4 D-Retro-Inverso Peptide)
What Is FOXO4-DRI? A Research Overview
FOXO4-DRI is a synthetic, cell-penetrating peptide designed to act as a senolytic — an agent studied for the selective elimination of senescent cells. Its name encodes both its origin and its chemistry: the sequence is derived from the human transcription factor FOXO4 (forkhead box O4), and it is built as a D-retro-inverso (DRI) isomer, meaning the residues are all of the D configuration and arranged in reverse order relative to the parent peptide. In the published literature it is classified mechanistically as an antagonist of the FOXO4–p53 protein-protein interaction.
A senolytic peptide that targets a protein interaction
Where many research peptides act on cell-surface receptors or enzymes, FOXO4-DRI is studied as an inhibitor of an intracellular protein-protein interaction. The foundational study by Baar and colleagues reported that a FOXO4 D-retro-inverso peptide perturbs the FOXO4–p53 interaction, causes p53 nuclear exclusion, and induces cell-intrinsic apoptosis selectively in senescent cells.[2] A later review of the FOXO4–p53 axis framed the same logic from the biology side: FOXO4 normally restrains p53-driven apoptosis in senescent cells, and a competing peptide can release that restraint.[3]
Lineage: de Keizer, Erasmus MC, and Baar et al. 2017
The peptide and its FOXO4–p53 senolytic mechanism trace to the laboratory of Peter L.J. de Keizer, with the foundational report — Baar et al., published in Cell in 2017 — describing both the molecular rationale and the first in-vivo demonstrations.[2] That work is associated with Erasmus MC in Rotterdam, with earlier related work at UCSF. Throughout this guide, every reported effect is preclinical — drawn from cell-culture systems and animal models — and FOXO4-DRI is one of several reagents in the Apex longevity and bioregulator research cluster studied for senescence biology.
FOXO4 Biology: A Forkhead Box O Transcription Factor
To understand why a FOXO4-derived peptide is a useful experimental tool, it helps to start with the protein the sequence comes from. FOXO4 is one of four mammalian members of the forkhead box O (FOXO) subfamily of transcription factors, alongside FOXO1, FOXO3, and FOXO6. These proteins share a conserved winged-helix DNA-binding domain and regulate the expression of genes involved in oxidative-stress resistance, cell-cycle control, metabolism, and apoptosis.
Regulation downstream of insulin/IGF-AKT signaling
A defining feature of FOXO transcription factors is that they sit downstream of the insulin and insulin-like-growth-factor (IGF) signaling axis. A review of FOXO biology in aging describes how, when this pathway is active, the kinase AKT phosphorylates FOXO factors and promotes their exclusion from the nucleus, switching off their transcriptional program; when the pathway is quiet or under stress, FOXO factors re-enter the nucleus and become transcriptionally active.[4] This conserved insulin/IGF–FOXO relationship is one of the most studied longevity pathways across model organisms.
FOXO4’s role in oxidative stress, survival, and senescence
Within that family, FOXO4 has a particular association with the cellular response to oxidative stress and with senescence. The FOXO4–p53 axis review notes that FOXO4 is upregulated in senescent cells, where it contributes to maintaining the senescent state by influencing p53 activity and localization.[3] It is this senescence-specific role — not FOXO4’s general transcriptional functions — that the FOXO4-DRI peptide is designed to exploit. Researchers placing FOXO4 within broader aging biology may also consult the Apex guide on Epithalon as a mechanistically distinct longevity research peptide.
Cellular Senescence and the SASP: Why Senescent Cells Persist
FOXO4-DRI cannot be understood in isolation from the biology of the cells it targets. Cellular senescence is a stress response in which a cell permanently exits the cell cycle but remains metabolically active, and its accumulation in tissues is a recurring theme in aging research.
Senescence as a hallmark of aging
The influential “hallmarks of aging” framework lists cellular senescence among the defined hallmarks — the interconnected processes whose accumulation drives organismal aging.[1] An international consensus statement subsequently catalogued the features by which senescent cells are identified: stable cell-cycle arrest, resistance to apoptosis, macromolecular damage, altered metabolism, and the secretory phenotype described below.[5] No single marker defines a senescent cell; the consensus is that a combination of features is required.
The senescence-associated secretory phenotype (SASP)
One of the most consequential features of senescent cells is the senescence-associated secretory phenotype, or SASP. The defining characterization by Coppé and colleagues described how senescent cells secrete a complex mixture of pro-inflammatory cytokines, chemokines, growth factors, and proteases, in a manner dependent on DNA-damage signaling and p53 status — a secretory program now understood as a key way senescent cells act on neighbouring tissue, contributing to chronic inflammation and tissue dysfunction in aging.[6]
Apoptosis resistance keeps senescent cells alive
A central reason senescent cells accumulate is that they actively resist programmed cell death. The senescence consensus describes apoptosis resistance as a defining property, and it is precisely this property that creates the rationale for senolytics: agents that selectively tip apoptosis-resistant senescent cells back toward death.[5] FOXO4-DRI is studied as one molecular approach to disabling a specific node of that apoptosis resistance.
The FOXO4-p53 Interaction That Keeps Senescent Cells Alive
The specific apoptosis-resistance node that FOXO4-DRI targets is the physical interaction between FOXO4 and p53. p53 is a master regulator that can, under sufficient stress, trigger apoptosis; in senescent cells, FOXO4 acts as a brake on that pro-apoptotic capacity.
FOXO4, PML bodies, and the restraint of p53
The FOXO4–p53 axis review describes the arrangement in detail: in senescent cells, FOXO4 is recruited to PML (promyelocytic leukaemia) nuclear bodies, where it interacts with p53 and helps keep p53 in a configuration that suppresses p53-driven apoptosis — maintaining the viability of the senescent cell rather than allowing it to die.[3] The same review notes that NMR and pull-down experiments show a FOXO4-DRI peptide competes with endogenous FOXO4 for p53 binding, providing biophysical support for the competitive mechanism.[3]
From the binding interface to a functional consequence
The original Baar study established the functional consequence of disrupting this interface: loss of the FOXO4–p53 association is followed by p53 nuclear exclusion and apoptosis in senescent cells.[2] Subsequent structural work refined exactly which region of p53 is engaged — the intrinsically disordered transactivation domain — providing the molecular framework for how a competing peptide can occupy that surface and displace endogenous FOXO4.[7] These are characterizations from biochemical and cell-based experiments and are not clinical findings.
D-Retro-Inverso Peptide Design: Why the ‘DRI’ Matters
The “DRI” in FOXO4-DRI refers to a specific peptide-engineering strategy that distinguishes it from an ordinary FOXO4-derived sequence. Understanding this design is essential to understanding why the peptide behaves as a stable, cell-active research tool.
All-D residues in reversed sequence
A D-retro-inverso peptide is built by two coordinated changes relative to a parent L-peptide: every amino acid is switched to its D (mirror-image) stereoisomer, and the entire sequence is reversed end to end. A review of retro-inverso peptide applications explains the logic: reversing the sequence while inverting the chirality of each residue produces a molecule whose side-chain spatial arrangement (topology) closely mimics that of the parent peptide, even though the backbone direction is inverted.[8] The result is a peptide that can engage the same binding partner as the original while presenting a chemically distinct backbone.
Protease resistance and a preserved interaction surface
The practical payoff of the DRI strategy is metabolic stability. Because proteases recognize the natural L-amino-acid backbone, a peptide made of D-residues is largely resistant to proteolytic degradation, giving retro-inverso analogs a substantially longer functional life than their L-peptide parents.[8] Applied to FOXO4, this means the FOXO4-DRI peptide can persist long enough in an experimental system to compete with endogenous FOXO4 for p53 binding — a competition demonstrated in the foundational study.[2]
Cell penetration and target engagement
For an inhibitor of an intracellular protein interaction, getting inside the cell is a prerequisite. The FOXO4-DRI design incorporates a cell-penetrating element so the peptide can reach the nuclear compartment where the FOXO4–p53 interaction occurs.[2] More recent structural work has refined exactly which part of p53 the peptide engages, a topic detailed in the next section.[7]
Mechanism of Action: p53 Nuclear Exclusion and Mitochondrial Apoptosis
With the target and the peptide chemistry established, the mechanism of FOXO4-DRI can be assembled as a sequence of molecular events — all characterized in cell and animal systems rather than in humans.
FOXO4-DRI competes for p53 → FOXO4–p53 disruption → p53 nuclear exclusion → intrinsic/mitochondrial apoptosis (senescent-cell selective)
In senescent cells, FOXO4 binds the intrinsically disordered transactivation domain of p53 and restrains p53-driven apoptosis. Published preclinical work describes FOXO4-DRI competing for that same disordered p53 domain: the cell-penetrating, protease-resistant peptide displaces endogenous FOXO4, which drives nuclear exclusion of the FOXO4-bound p53. The loss of nuclear p53 restraint engages the intrinsic, mitochondrial apoptosis pathway, selectively in senescent cells while sparing proliferating cells; in endothelial-cell models, this shift was reported as increased BAX and cleaved caspase-3 with decreased BCL2. (Hu et al., 2026) Every step is characterized in cell and animal systems. Baar et al. (2017), Cell.
Competing for the disordered p53 transactivation domain
The most precise account of where FOXO4-DRI acts comes from a 2025 structural study, which identified the intrinsically disordered transactivation domain of p53 as the molecular target engaged by both FOXO4 and the FOXO4-DRI senolytic peptide.[7] Because FOXO4 and the DRI peptide compete for the same disordered region of p53, the peptide can displace endogenous FOXO4 from p53 — the molecular event that initiates the downstream cascade.
p53 nuclear exclusion as the pivotal step
Disrupting the FOXO4–p53 interaction changes where p53 goes inside the cell. The foundational study reported that loss of the interaction leads to nuclear exclusion of FOXO4-bound p53 and triggers cell-intrinsic apoptosis in senescent cells.[2] A worked example of this step comes from a senescent keloid-fibroblast model, in which FOXO4-DRI promoted apoptosis by driving nuclear exclusion of phosphorylated p53 (p53 phosphorylated on serine 15), tying the nuclear-exclusion mechanism to a concrete cell system.[9]
Intrinsic / mitochondrial apoptosis: BAX and cleaved caspase-3
The downstream cell-death program is the intrinsic, mitochondrial apoptosis pathway. In a senescent-endothelial-cell model, FOXO4-DRI prevented FOXO4–p53 binding and shifted the apoptotic balance: it increased the pro-apoptotic effector BAX and cleaved caspase-3 while decreasing the anti-apoptotic protein BCL2 — the molecular signature of intrinsic mitochondrial apoptosis.[10] Taken together, the literature describes a coherent chain: peptide competes for the disordered p53 transactivation domain, displaces FOXO4, p53 is excluded from the nucleus, and the intrinsic apoptosis machinery is engaged — selectively in senescent cells, as the next section details. Every step in this chain is a preclinical finding.
Selectivity for Senescent Over Proliferating Cells
The defining experimental claim for any senolytic is selectivity: it should eliminate senescent cells while sparing healthy proliferating ones. For FOXO4-DRI, this selectivity is documented in cell models and is the reason the FOXO4–p53 node is an attractive target.
Selective clearance in a chondrocyte model
A clear demonstration comes from work on in-vitro-expanded human chondrocytes. Huang and colleagues reported that FOXO4-DRI selectively removed highly expanded chondrocytes — cells driven into senescence by extensive passaging — while sparing minimally expanded, non-senescent control cells, establishing senescence-selectivity in a cartilage cell system.[11] The contrast between expanded and minimally expanded cells is the experimental basis for the selectivity claim.
Selectivity tied to the apoptosis mechanism
Selectivity in the FOXO4-DRI literature is mechanistically linked to the fact that the FOXO4–p53 brake is engaged specifically in senescent cells. The endothelial-cell study, working in oxygen-glucose-deprivation-induced senescent cells, reported the BAX / cleaved-caspase-3 apoptotic shift in those senescent cells, consistent with the idea that the peptide acts where the FOXO4–p53 restraint is operating.[10] The foundational study likewise framed the apoptotic effect as selective for senescent over non-senescent cells.[2] These are cell-model observations; selectivity demonstrated in one cell type should not be assumed to generalize uniformly across all tissues.
In Vivo Mouse Findings: Aged and Fast-Aging Models
Beyond cell culture, the FOXO4-DRI literature includes a set of mouse studies. These are animal-model findings reported strictly as research results; none establishes anything in humans, and none should be read as evidence of clinical benefit.
The foundational aging-mouse results
The most consequential in-vivo data come from the foundational study. Baar and colleagues reported that the FOXO4 D-retro-inverso peptide neutralized doxorubicin-induced chemotoxicity in mice and, in fast-aging XpdTTD/TTD mice and naturally aged mice, restored fitness, fur density, and renal function.[2] These outcomes — measured in two distinct mouse contexts, a fast-aging genetic model and natural aging — were the results that first drew broad research attention to the peptide.
Senescent Leydig cells in aged mice
Subsequent work extended the model range. Zhang and colleagues studied FOXO4-DRI in naturally aged mice and reported that it selectively induced apoptosis of senescent Leydig cells and improved the testicular microenvironment, with associated changes in age-related testosterone secretion.[12] This is an animal-model study of a specific senescent-cell population, reported as preclinical research.
A disease-model context: pulmonary fibrosis
FOXO4-derived peptide work has also been applied in a disease model. Han and colleagues reported that a FOXO4 peptide reduced senescent-cell burden and the associated secretory phenotype and attenuated bleomycin-induced pulmonary fibrosis in mice, illustrating senolytic activity in a fibrosis context.[13] As with every other finding in this guide, these are model-specific results in mice or isolated cells, not demonstrations of efficacy in any clinical sense.
FOXO4-DRI vs Other Senolytics (Research Context)
FOXO4-DRI is one entry in a broader senolytics research field, and the most useful way to situate it is by mechanism — how its peptide-based, protein-interaction-targeting approach differs from the small molecules that opened the field.
FOXO4-DRI vs Common Small-Molecule Senolytics (Research Context Only)
| Attribute | FOXO4-DRI | Dasatinib + Quercetin (D+Q) | Navitoclax (ABT-263) |
|---|---|---|---|
| Class | D-retro-inverso peptide (PPI inhibitor) | Tyrosine-kinase inhibitor + flavonoid (small molecules) | BH3-mimetic small molecule |
| Primary molecular target | FOXO4–p53 interaction | SRC/ephrin and PI3K anti-apoptotic networks | BCL-2 / BCL-xL |
| Proposed senolytic action | Releases p53 → nuclear exclusion → intrinsic apoptosis | Disables senescent-cell anti-apoptotic survival pathways | Inhibits BCL-2/BCL-xL to trigger apoptosis |
| Selectivity emphasis | Senescent over proliferating cells (cell models) | Cell-type-dependent senolysis | Senescent cells incl. haematopoietic stem cells (mouse) |
| Key reference | Baar 2017, Cell (PMID 28340339) | Zhu 2015, Aging Cell (PMID 25754370) | Chang 2016, Nat Med (PMID 26657143) |
| Evidence stage | Preclinical (in-vitro + mouse) | Preclinical + early clinical (other compounds) | Preclinical (mouse) |
| Modality | Cell-penetrating peptide | Oral small molecules | Oral small molecule |
The genetic proof-of-concept that motivates senolysis
The rationale for clearing senescent cells at all rests on a genetic experiment. Baker and colleagues, using the INK-ATTAC transgenic mouse, showed that selectively removing naturally occurring p16Ink4a-positive senescent cells extended healthspan, establishing a causal proof-of-concept that senescent-cell removal can benefit aged tissue.[14] Pharmacological senolytics, including FOXO4-DRI, are studied as ways to achieve a similar outcome without a genetic tool.
Small-molecule senolytics: dasatinib + quercetin and navitoclax
The first pharmacological senolytics were small molecules. Zhu and colleagues identified dasatinib and quercetin by targeting the anti-apoptotic survival networks that senescent cells depend on.[15] Separately, Chang and colleagues identified navitoclax (ABT-263), an inhibitor of BCL-2 and BCL-xL, as a senolytic that cleared senescent cells and rejuvenated aged haematopoietic stem cells in mice.[16] Both act on anti-apoptotic protein networks as small molecules.
A peptide PPI-inhibitor versus small-molecule mechanisms
FOXO4-DRI differs from both at the level of mechanism. Rather than broadly inhibiting an anti-apoptotic protein family or a kinase network, it disrupts one defined protein-protein interaction — FOXO4 binding to p53 — to release the cell’s own p53-driven apoptosis program.[2] This is a comparison of research pharmacology across distinct mechanistic classes, not a comparison of approved therapies; none of these compounds is presented here as a treatment. The comparison table above summarizes the contrasts.
Reported Research Applications and Model Systems
Surveying the experimental systems in which FOXO4-DRI has appeared serves as a map of the literature — useful for researchers orienting to what has and has not been studied. Every system below is in-vitro or animal-model.
A catalogue of studied systems
The cell-based literature spans several senescent-cell types: in-vitro-expanded human chondrocytes, where selective removal of senescent cells was reported;[11] oxygen-glucose-deprivation-induced senescent endothelial cells, where the BAX / cleaved-caspase-3 apoptotic program was documented;[10] and senescent keloid fibroblasts, where apoptosis proceeded through nuclear exclusion of phosphorylated p53.[9] The animal-model literature adds senescent Leydig cells in aged mice[12] and a bleomycin pulmonary-fibrosis model.[13]
What the breadth does and does not mean
The range of model systems illustrates the kinds of research questions the peptide has been used to probe — cartilage, vascular, dermal, reproductive, and pulmonary senescence — but breadth of study is not the same as established efficacy. These are independent preclinical reports using different senescence-induction methods and different readouts; consistency of the FOXO4–p53 mechanism across them is suggestive but does not constitute clinical evidence. Researchers comparing aging-research peptides across mechanisms may also review the Apex guides on MOTS-c and SS-31 (elamipretide), which act on mitochondrial rather than senescence pathways.
Handling, Reconstitution and Purity Verification
Apex provides handling context for laboratory work only; nothing in this section constitutes a dosing recommendation for humans, and no human dosing protocol for FOXO4-DRI exists in the cited literature. The peptide is a research-grade chemical reagent, and the considerations below concern experimental reproducibility, not pharmacology.
Lyophilized handling and reconstitution
FOXO4-DRI ships as a lyophilized powder. As a relatively large synthetic peptide (catalog molecular weight approximately 4,800 g/mol), it is generally reconstituted in a suitable research-grade solvent immediately before use, with the dry powder stored at −20°C and protected from light and moisture, and reconstituted aliquots kept cold and freeze-thaw cycling minimized to preserve integrity. These are general peptide-handling conventions rather than compound-specific stability data. For protocol detail, consult the Apex guides on how to reconstitute peptides and the peptide storage guide.
The DRI advantage and why purity still matters
One handling implication follows directly from the chemistry: because the D-retro-inverso design confers protease resistance, FOXO4-DRI is inherently more stable against enzymatic degradation than an equivalent L-peptide. That stability is a feature of the molecule, not a substitute for verification — a peptide of this length must still be confirmed for identity and purity, since synthesis errors, incomplete sequences, or impurities would change the molecule being tested. Identity and purity (≥99%) should be confirmed against a certificate of analysis reporting HPLC purity and mass-spectrometry identity. Background on interpreting these documents is available in the Apex primers on how to read a peptide CoA and HPLC testing for peptide purity.
A note on identity facts
FOXO4-DRI is a custom research peptide, and several common catalog identity fields are honestly listed as not specified. There is no assigned CAS number, no single canonical PubChem CID, and no catalog-authoritative molecular formula for this particular DRI peptide; third-party molecular-formula values circulate but are not treated as authoritative here. The catalog molecular weight of approximately 4,800 g/mol and the ≥99% HPLC + MS purity specification are the load-bearing identity facts a research-grade lot should document.
Research-Use Status and Sourcing Research-Grade FOXO4-DRI
For any FOXO4-DRI experiment, reproducibility depends on knowing exactly what is in the vial. Because FOXO4-DRI is a custom senolytic peptide whose identity and purity directly affect experimental outcomes, research-grade material should be accompanied by analytical documentation rather than label claims alone.
Research-use-only designation
FOXO4-DRI has no approved pharmaceutical formulation and no regulatory approval anywhere. It is supplied strictly for in-vitro and preclinical laboratory research and is not for human or veterinary use, diagnosis, treatment, or any clinical application. Unlike some research compounds that share a molecule with an approved drug, FOXO4-DRI is a custom research peptide with no pharmaceutical counterpart; the distinction between research-grade reagents and finished pharmaceutical products is discussed in the Apex guide on research-grade vs pharmaceutical-grade peptides.
HPLC purity and MS identity verification
Apex supplies FOXO4-DRI at ≥99% purity, verified by reversed-phase HPLC for purity and by mass spectrometry for identity. Each lot is documented with a per-batch certificate of analysis available through the lab-verified CoA archive; researchers should review the lot-specific CoA rather than relying on a generic specification. The Apex editorial standards and research library document how each guide is sourced and reviewed.
Adjacent longevity-research reagents
Researchers assembling a longevity- and senescence-focused reagent panel often pair FOXO4-DRI with mechanistically distinct compounds; adjacent guides such as Epithalon and MOTS-c situate it within the broader research context, and the items below are available as research reagents.
FOXO4-DRI and Adjacent Longevity Research Reagents
FOXO4-DRI
Senolytic D-retro-inverso peptide targeting the FOXO4–p53 interaction; lyophilized, supplied at ≥99% purity verified by HPLC and mass spectrometry for research use only.
View ProductEpithalon
Epithalon (epitalon) tetrapeptide; longevity and telomere-biology research reagent.
View ProductFrequently Asked Questions
What is FOXO4-DRI?
FOXO4-DRI is a senolytic research peptide built on the FOXO4 sequence using a D-retro-inverso design. In published preclinical studies it disrupts the FOXO4-p53 interaction that helps senescent cells evade apoptosis, first reported by Baar and colleagues in Cell in 2017. It is a research-use-only chemical reagent supplied by Apex Laboratory for in-vitro and preclinical work, not a drug.
What does ‘DRI’ (D-retro-inverso) mean?
DRI means the peptide is built from D-amino acids arranged in reverse sequence relative to the parent peptide. This topochemical strategy preserves the spatial arrangement of side chains while making the backbone resistant to proteases, which is why retro-inverso analogs are studied as more stable surrogates of natural peptides (Doti 2021). The added stability lets FOXO4-DRI persist long enough to compete with endogenous FOXO4 for p53.
How does FOXO4-DRI work at the molecular level?
In senescent cells, FOXO4 binds p53 and restrains p53-driven apoptosis. In reported cell and mouse studies, FOXO4-DRI competes for the intrinsically disordered p53 transactivation domain (Bourgeois 2025), displaces FOXO4, and promotes nuclear exclusion of p53. This engages intrinsic mitochondrial apoptosis, with increased BAX and cleaved caspase-3 and decreased BCL2 (Hu 2026), selectively in senescent cells. These are preclinical findings.
Who developed FOXO4-DRI?
The peptide and its FOXO4-p53 senolytic mechanism were reported by Peter de Keizer and colleagues, with the foundational study Baar et al. published in Cell in 2017. The work is associated with Erasmus MC in Rotterdam, with earlier related work at UCSF. It remains a research tool, and all reported effects come from cell-culture and animal-model experiments.
What have mouse studies reported about FOXO4-DRI?
In the foundational study, the FOXO4 D-retro-inverso peptide was reported to neutralize doxorubicin chemotoxicity and to restore fitness, fur density, and renal function in fast-aging XpdTTD and naturally aged mice (Baar 2017). Subsequent preclinical work examined senescent Leydig cells in aged mice (Zhang 2020) and a bleomycin pulmonary-fibrosis model (Han 2022). All of these are animal-model findings for research purposes only and do not establish anything in humans.
How is FOXO4-DRI different from senolytics like dasatinib, quercetin, or navitoclax?
Dasatinib plus quercetin (Zhu 2015) and navitoclax or ABT-263 (Chang 2016) are small molecules that act on kinase and BCL-2-family anti-apoptotic networks. FOXO4-DRI is a peptide that directly disrupts one specific protein-protein interaction, FOXO4 binding to p53, to release the cell’s own p53-driven apoptosis. They are distinct mechanistic classes studied within the same senolytic research field, and none is presented here as an approved treatment.
Is FOXO4-DRI a medicine or approved for any use?
No. FOXO4-DRI has no approved pharmaceutical formulation and no regulatory approval. It is supplied strictly as a research-use-only chemical reagent for in-vitro and preclinical laboratory research and is not for human or veterinary use. Unlike some research compounds, it does not share a molecule with an approved drug; it is a custom research peptide with no pharmaceutical counterpart.
How should FOXO4-DRI be stored and verified?
It ships as a lyophilized powder and is generally stored at minus 20 degrees Celsius, protected from light and moisture, with reconstituted material kept cold and freeze-thaw cycles minimized. Although the D-retro-inverso design makes the peptide protease-resistant, identity and purity (greater-than-or-equal-to 99%) should still be confirmed against a certificate of analysis showing HPLC purity and mass-spectrometry identity. Note that no CAS number, canonical PubChem CID, or catalog-authoritative molecular formula is assigned to this custom peptide.
Continue Your Research
Researchers building broader context across the Apex Research Library may find the following references useful:
- Longevity & Bioregulator Research Peptides — the cluster hub situating FOXO4-DRI among senescence and aging-research reagents
- Epithalon Research Guide — a mechanistically distinct longevity peptide studied in telomere and aging biology
- MOTS-c Research Guide — a mitochondrial-derived peptide studied as a metabolic signal in aging research
- SS-31 (Elamipretide) Research Guide — a mitochondria-targeted peptide that contrasts with FOXO4-DRI’s senescence mechanism
- Research-Grade vs Pharmaceutical-Grade Peptides — why a research reagent is categorically distinct from a finished pharmaceutical product
- How to Reconstitute Peptides — general protocol for preparing lyophilized peptides such as FOXO4-DRI for in-vitro work
- Peptide Storage Guide — storage and freeze-thaw handling that preserve a lyophilized synthetic peptide
- How to Read a Peptide Certificate of Analysis — interpreting HPLC purity and mass-spectrometry identity data on a lot-specific CoA
Research Use Disclaimer
All FOXO4-DRI products and the information in this guide are intended strictly for in-vitro and preclinical laboratory research. FOXO4-DRI is a research-grade chemical reagent and is not a drug, dietary supplement, or therapeutic product. It is not approved by the FDA, EMA, or any other regulatory authority, it has no approved indication anywhere, and no approved pharmaceutical formulation of it exists. It is not for human or veterinary consumption, diagnosis, treatment, or any clinical use. The senescence, FOXO4-p53 mechanism, apoptosis, and aging-model findings summarized here derive from cell-culture and animal-model studies and are presented for research context only; they do not constitute therapeutic, efficacy, safety, or lifespan claims. Researchers are responsible for compliance with all applicable institutional, local, and national regulations governing the acquisition, handling, and use of research chemicals.
